Medexus Sets Date for Q3 2026 Earnings Call and Webcast

An update from Medexus Pharmaceuticals Inc ( (TSE:MDP) ) is now available.

Medexus Pharmaceuticals has scheduled a conference call on February 12, 2026, to discuss its financial results for the third fiscal quarter ended December 31, 2025, with financial statements and management’s discussion and analysis to be filed after markets close on February 11. The company will provide both a live webcast and replay of the call through its investor relations website, signaling continued transparency with shareholders and stakeholders as it reports on its performance in the specialty and rare-disease pharmaceutical market.

The most recent analyst rating on (TSE:MDP) stock is a Hold with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Spark’s Take on TSE:MDP Stock

According to Spark, TipRanks’ AI Analyst, TSE:MDP is a Neutral.

Medexus Pharmaceuticals Inc’s overall stock score reflects mixed financial performance and weak technical indicators. The high P/E ratio suggests overvaluation, while the earnings call provides some optimism with successful product launches and reimbursement improvements. However, declining revenue and competitive pressures pose significant risks.

To see Spark’s full report on TSE:MDP stock, click here.

More about Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals is a specialty pharmaceutical company with a strong commercial presence in North America, focused on innovative and rare disease treatments. The company concentrates on hematology, hematology-oncology, rheumatology, and allergy therapies, targeting niche therapeutic areas where there is significant unmet medical need.

Average Trading Volume: 46,285

Technical Sentiment Signal: Buy

Current Market Cap: C$91.75M

For an in-depth examination of MDP stock, go to TipRanks’ Overview page.